title: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.
abstract: The likelihood of a sustained response to a course of interferon in patients with chronic hepatitis C correlates with several clinical and viral factors, including age, viral genotype and initial levels of hepatitis C virus (HCV) RNA in serum. The role of race and ethnicity has not been assessed. We evaluated the association of race with response to interferon in a large randomized, controlled trial using either consensus interferon (9 microg) or interferon alfa-2b (3 million units) given three times weekly for 24 weeks. African-American patients participating in the study were similar to white patients in mean age (43 vs. 42 years) and baseline levels of HCV RNA (3.6 vs. 3.0 million copies/mL) but had lower rates of cirrhosis (5% vs. 12%) and more frequently had viral genotype 1 (88% vs. 66%: P =.004). Most strikingly, the rates of end-of-treatment and sustained virological responses were lower among the 40 African-American patients (5% and 2%) than among the 380 white patients (33% and 12%) (P =.04 and.07). Rates of response among Hispanic and Asian-American patients were not statistically different than non-Hispanic white patients. Median viral levels decreased by week 24 of therapy by 2.5 logs in white patients (from 3.0 to 0.012 million copies/mL) but by only 0.5 logs among African- American patients (from 3.6 to 1.8 million copies/mL). Thus, there are marked racial differences in virological responses to interferon in hepatitis C that must be considered in assessing trials of interferon therapy and in counseling patients regarding treatment. The differences in response rates are as yet unexplained.
authors.affiliation: University of Miami, Miami, FL, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: Reddy
authors.forename: J H
authors.initials: JH
authors.lastname: Hoofnagle
authors.forename: M J
authors.initials: MJ
authors.lastname: Tong
authors.forename: W M
authors.initials: WM
authors.lastname: Lee
authors.forename: P
authors.initials: P
authors.lastname: Pockros
authors.forename: E J
authors.initials: EJ
authors.lastname: Heathcote
authors.forename: D
authors.initials: D
authors.lastname: Albert
authors.forename: T
authors.initials: T
authors.lastname: Joh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D019698:Hepatitis C, Chronic / Q000208:ethnology / Q000628:therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D007372:Interferons